Current therapeutic strategies for essential thrombocythemia (ET) are mainly considered to prevent thrombo-hemorrhagic events, without increasing the rate of fibrotic progression or leukemic evolution.
To treat the patients appropriately, the precise diagnosis of ET is essential.
Although approximately 30% of ET cases are diagnosed as
